Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Garcia
Jorge A
JA
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. garciaj4@cff.org
Hutson
Thomas E
TE
Shepard
Dale
D
Elson
Paul
P
Dreicer
Robert
R